Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (999)	6/15/2012 11:41:15 AM
From: The Ox	Read Replies (2) \| Respond to of 8239

Off recent highs: WYNN down 40% VMW down 26% CAT down 26% QCOM down 19% PCLN down 18% GOOG down 17%

To: The Ox who wrote (999)	6/21/2012 10:27:31 AM
From: The Ox	Read Replies (1) \| Respond to of 8239

8:00AM Chelsea Therapeutics reports combined Northera data from two Phase 3 trials confirm symptom improvement in patients with neurogenic OH ( CHTP) 1.31 : Co reports results from an integrated dataset of two phase 3 studies, Study 301 and Study 302, which showed that patients treated with Northera experienced improvements in their symptoms of Neurogenic Orthostatic Hypotension as measured by the Orthostatic Hypotension Questionnaire composite score and a number of individual symptoms, including dizziness. Additional data from co's integrated analysis showed that droxidopa-treated patients experienced improvements in their symptoms of Neurogenic OH as measured by the Orthostatic Hypotension Symptom Assessment score; 3 of the 6 items of the OHSA (dizziness, weakness, fatigue); the Orthostatic Hypotension Daily Activity Scale composite score; and all 4 individual items of the OHDAS Treatment with droxidopa showed low rates of supine hypertension.